FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367302408> ?p ?o ?g. }

• W4367302408 abstract "<h3>Objective:</h3> Topiramate is used for neonatal seizures; however, there is a paucity of data on the efficacy and safety of topiramate for neonatal seizures. In this study we describe the efficacy and safety of one institution’s experience with topiramate for neonatal seizures. <h3>Background:</h3> Currently there are no FDA approved drugs for neonatal seizures and a paucity of data to guide their management.¹ Neonatal seizures are an important clinical problem associated with poor outcomes. Therapeutic management of neonatal seizures may improve long term outcome for patients. Topiramate is being used off-label for neonatal seizures; however, there is limited data in the literature on the efficacy and safety of topiramate in the neonatal population.² Studies in animal models suggest topiramate is effective both as an antiepileptic and neuroprotective agent in newborns.³ <h3>Design/Methods:</h3> A retrospective review was performed evaluating safety and seizure frequency response to topiramate. Only qualitative safety and seizure data from medical records, progress notes and EEG reports could be extracted and were categorized as decreased, unchanged or increased. Data from 7 patients who received topiramate for onset of seizures between the ages of 35–45 weeks gestation were collected and reviewed from January 2011 to December 2020. Topiramate doses ranged from 2 mg/kg/day to 18 mg/kg/day. <h3>Results:</h3> In the initial response, defined as 24hr after administration, there was decrease of clinical seizures confirmed with EEG in 71.4% of participants. At the 6 months follow up, 42.8% continued to have improvement. There were no reported adverse effects of topiramate. <h3>Conclusions:</h3> This case series suggests topiramate is effective for neonatal seizures especially for short-term control and may be as a treatment alternative to other more commonly used antiepileptics that have long-term consequences on brain development. Further investigation is warranted to explore the efficacy of topiramate for neonatal seizures. <b>Disclosure:</b> Ms. Zheng has nothing to disclose. Dr. Hall has nothing to disclose. Mr. Kneepkens has nothing to disclose. Dr. Wang has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ovid Therapeutics." @default.
• W4367302408 created "2023-04-29" @default.
• W4367302408 creator A5006225358 @default.
• W4367302408 creator A5033335842 @default.
• W4367302408 creator A5035766472 @default.
• W4367302408 creator A5059785686 @default.
• W4367302408 date "2023-04-25" @default.
• W4367302408 modified "2023-09-30" @default.
• W4367302408 title "A Case Series in the Use of Topiramate for Neonatal Seizures (P13-1.008)" @default.
• W4367302408 doi "https://doi.org/10.1212/wnl.0000000000203746" @default.
• W4367302408 hasPublicationYear "2023" @default.
• W4367302408 type Work @default.
• W4367302408 citedByCount "0" @default.
• W4367302408 crossrefType "proceedings-article" @default.
• W4367302408 hasAuthorship W4367302408A5006225358 @default.
• W4367302408 hasAuthorship W4367302408A5033335842 @default.
• W4367302408 hasAuthorship W4367302408A5035766472 @default.
• W4367302408 hasAuthorship W4367302408A5059785686 @default.
• W4367302408 hasConcept C118552586 @default.
• W4367302408 hasConcept C126322002 @default.
• W4367302408 hasConcept C167135981 @default.
• W4367302408 hasConcept C187212893 @default.
• W4367302408 hasConcept C195910791 @default.
• W4367302408 hasConcept C197934379 @default.
• W4367302408 hasConcept C2777683783 @default.
• W4367302408 hasConcept C2778186239 @default.
• W4367302408 hasConcept C2908647359 @default.
• W4367302408 hasConcept C42219234 @default.
• W4367302408 hasConcept C71924100 @default.
• W4367302408 hasConcept C99454951 @default.
• W4367302408 hasConceptScore W4367302408C118552586 @default.
• W4367302408 hasConceptScore W4367302408C126322002 @default.
• W4367302408 hasConceptScore W4367302408C167135981 @default.
• W4367302408 hasConceptScore W4367302408C187212893 @default.
• W4367302408 hasConceptScore W4367302408C195910791 @default.
• W4367302408 hasConceptScore W4367302408C197934379 @default.
• W4367302408 hasConceptScore W4367302408C2777683783 @default.
• W4367302408 hasConceptScore W4367302408C2778186239 @default.
• W4367302408 hasConceptScore W4367302408C2908647359 @default.
• W4367302408 hasConceptScore W4367302408C42219234 @default.
• W4367302408 hasConceptScore W4367302408C71924100 @default.
• W4367302408 hasConceptScore W4367302408C99454951 @default.
• W4367302408 hasLocation W43673024081 @default.
• W4367302408 hasOpenAccess W4367302408 @default.
• W4367302408 hasPrimaryLocation W43673024081 @default.
• W4367302408 hasRelatedWork W1858716145 @default.
• W4367302408 hasRelatedWork W2037133700 @default.
• W4367302408 hasRelatedWork W2049498361 @default.
• W4367302408 hasRelatedWork W2061886507 @default.
• W4367302408 hasRelatedWork W2110954332 @default.
• W4367302408 hasRelatedWork W2728781949 @default.
• W4367302408 hasRelatedWork W2793900558 @default.
• W4367302408 hasRelatedWork W2997183136 @default.
• W4367302408 hasRelatedWork W3125081545 @default.
• W4367302408 hasRelatedWork W4210625460 @default.
• W4367302408 isParatext "false" @default.
• W4367302408 isRetracted "false" @default.
• W4367302408 workType "article" @default.